Françoise de Craecker
Director/Board Member at X4 PHARMACEUTICALS, INC.
Net worth: 97 634 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Wyzga | M | 69 | 11 years | |
| Paula Ragan | M | 54 | 10 years | |
| Adam Mostafa | M | 44 | 6 years | |
| Gregg Lapointe | M | 65 | 9 years | |
| Laurence Rodriguez | F | 56 | 3 years | |
| Mary DiBiase | M | 63 | 7 years | |
| Kim Lee | M | - | 10 years | |
| Paul Hoelscher | M | 59 | 8 years | |
| Sissel Rodahl | F | - | 6 years | |
| Alison Lawton | F | 62 | 4 years | |
| Gary Bridger | M | 61 | 6 years | |
| Maritza McIntyre | M | 58 | 5 years | |
| David McGirr | M | 69 | 7 years | |
| Simone Seiter | M | 57 | 7 years | |
| Murray Stewart | M | 63 | 5 years | |
| Elsy Boglioli Hofman | F | 42 | 4 years | |
| Magali Taiel | M | - | 6 years | |
| Bill Aliski | M | 75 | 5 years | |
| Marion Ghibaudo | M | - | 3 years | |
| Brian Bowersox | M | - | - | |
| Christophe Arbet-Engels | M | - | 1 years | |
| R. Woods | M | 56 | 1 years | |
| Julio Benedicto | M | - | 7 years | |
| Mark Baldry | M | 60 | 2 years | |
| Art Taveras | M | 60 | 4 years | |
| Cédric Moreau | M | 37 | 5 years | |
| Timothy Walbert | M | 57 | 8 years | |
| Scott Jeffers | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bernard Gilly | M | 67 | 12 years | |
| René Russo | M | 49 | 6 years | |
| Sean Nolan | M | 56 | 3 years | |
| Philip Donenberg | M | 63 | 2 years | |
| Bong Koh | M | - | - | |
| Tamara Joseph | F | 61 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Terrence Kearney | M | 69 | 2 years | |
| Daniel Welch | M | 66 | 2 years | |
| Paul Manning | M | 68 | 4 years | |
| Derek Meisner | M | 53 | 3 years | |
| Doug Treco Treco | M | 66 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 17 years |
| Kurt C. Gunter | M | 69 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| Brian K. Kaspar | M | - | - | |
| Peter Goodfellow | M | 72 | 9 years | |
| Natalie Mount | M | - | 4 years | |
| Lisa Deschamps | F | 52 | 3 years | |
| Frank Verwiel | M | 61 | 3 years | |
| Fariborz Kamal | M | 61 | 1 years | |
| Ronny Mosston | F | - | - | |
| Isabelle Scarabin | F | - | 8 years | |
| Craig Osten | M | - | - | |
| Ross Moat | M | 43 | 1 years | |
| Angela Thedinga | F | 42 | 1 years | |
| Mihaela MacNair | F | - | 1 years | |
| Philippe Motté | M | 64 | - | |
| Shariq Ali | M | - | 2 years | |
| Ritu Shah | F | 48 | 1 years | |
| Karolyn Park | F | - | 1 years | |
| Leigh Shaw | M | - | 2 years | |
| Petra Kaufmann | M | 58 | 2 years | |
| Robert May | M | 56 | 2 years | |
| Sean Gaskell | M | 42 | 2 years | |
| Clothilde Caillet | M | - | - | |
| Diego Cadavid | M | 58 | 2 years | |
| Obed M. Cepeda | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Thomas Gidoin | M | 41 | 9 years | |
| William J. Fallon | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Thomas Sciascia | M | 70 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Gregory Perry | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 years |
| Neil Kirby | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Konstantinos Andrikopoulos | M | 58 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Daniel Geffken | M | 67 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 6 years |
| Jonathan Leff | M | 55 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| James Edward Thomas | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Michael Astrue | M | 67 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Renato Fuchs | M | 80 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 4 years |
| Christoph Adams | M | 67 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 7 years |
| Rick Modi | M | 55 | 2 years | |
| Shirish Hirani | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Joao Siffert | M | 60 | 1 years | |
| Anthony S. Murabito | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 years |
| Joseph Nolan | M | 61 | - | |
| Ivana Magovcevic-Liebisch | M | 56 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Sylvia Cheung | F | 50 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| Sukumar Nagendran | M | 58 | 3 years | |
| R. Session | M | 45 | 1 years | |
| Adi Mohanty | M | 57 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Carrie Melvin | F | 56 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 69 | 80.23% |
| France | 19 | 22.09% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Françoise de Craecker
- Personal Network
